CHARLESTON, S.C.--(BUSINESS WIRE)--Zestra Laboratories, Inc., the developer and maker of patented Zestra® Feminine Arousal Fluid, today announced the appointment of Younis Zubchevich as chief executive officer. In this capacity, Zubchevich will immediately implement the company’s expansion plans, oversee day-to-day operations and help raise Zestra’s product brand awareness and distribution.
“Younis began two years ago as our ‘hands-on’ investment banker, and he has proven highly instrumental in the planning and execution of our growth domestically and abroad,” said Martin Crosby, chairman and chief science officer of Zestra Laboratories. “Younis has played major roles in implementing our growth objectives on target, which has placed us in almost 30,000 points of retail distribution nationwide. The company is focused on driving the Zestra® brand and its global growth. We are quickly expanding our ‘long-term lead’ as the first option for millions of women who experience sexual difficulties and intimacy problems. Younis is a driver with financial, business and investment expertise that has enabled us to rapidly increase product awareness and top-line sales results and successfully bridge our activities within the investment banking community.”
Zestra Laboratories is the consumer health products company that developed, manufactures, markets, and distributes Zestra® Feminine Arousal Fluid (US Patent 6,737,084). Zestra® is the only consumer product available that is clinically shown to quickly increase female sexual sensation, arousal, pleasure, and improve women’s sexual experiences.
“Our key objectives include building trust with the millions of women we can serve, helping them obtain the pleasurable experiences they may not have had in many years and improving their sexuality and intimacy in a healthy, natural way,” Zubchevich said. “If we can continue to help satisfy this basic human need on a global scale, we will achieve all of the high business goals and expectations we have set for our company.”
Zubchevich added: “Zestra® is the first and only women’s consumer product that is proven to quickly address widespread sexual problems that impact intimacy. As we build our distribution domestically and abroad, and as our current clinical trial progresses to completion, we are confident we can significantly grow our brand equity. We recognize the demand for an all-natural product that is clinically proven, affordable and easy to use. In what we understand to be a $6 billion market, our challenge is to ensure that everyone becomes aware that Zestra® Feminine Arousal Fluid is that solution, and it’s available now.”
Prior to joining Zestra, Zubchevich served as president and chairman of Gryphon Financial Securities Corp., a NASD member and SEC registered broker-dealer. He also served in similar capacities with York Avenue Holding Corp., Gryphon’s parent. Before that, he served as a senior officer with several international investment banks. Zubchevich, who has worked in numerous capacities within the securities industry, has focused his career on developing corporate finance transactions in the form of private placements and public offerings for emerging growth companies.
Zestra Laboratories, Inc., a specialty consumer health products company, is the developer, manufacturer and distributor of Zestra® Feminine Arousal Fluid, a scientific breakthrough in women’s sexual health and intimacy. Zestra® is the only consumer product available that is clinically shown to quickly increase female sexual sensation, arousal, pleasure, and improve sexual experiences for women. The commercialization of Zestra® is the result of seven years of research and clinical testing. Non-prescription Zestra®, in a randomized, double-blind placebo-controlled, crossover clinical trial increased satisfaction with sexual arousal in 85% of women experiencing arousal problems, and in 95% of women not experiencing arousal problems. This study was first published in the Journal of Sex and Marital Therapy. The all-natural Zestra® formulation is topically applied and begins increasing female sexual pleasure and arousal in 3 to 5 minutes. For complete information, visit www.zestra.com.
Editor’s Notes:
Photographs of Younis Zubchevich are available upon request
Samples and photographs of Zestra® Feminine Arousal Fluid are available upon request
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding Zestra Laboratories contained in this news release that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes,” “plans,” “hopes,” or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. All forward-looking statements speak only as of the date of this news release. Zestra Laboratories, Inc. undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: Zestra Laboratories, Inc. Younis Zubchevich, 843-402-0901 Fax: 843-402-0919 younisz@zestra.com www.zestra.com or Media Relations: Hart Marketing Communications Jolie Balido, 305-586-0419 jolie@hartmc.com or Jeannie Salameh, 305-586-0419 jeannie@hartmc.com
Source: Zestra Laboratories Inc.
